8158 On Other Exchanges
Symbol
Exchange
8158 is not on other exchanges.

china regenerative medicine (8158) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHINA REGENERATIVE MEDICINE (8158)

Related News

No related news articles were found.

china regenerative medicine (8158) Related Businessweek News

No Related Businessweek News Found

china regenerative medicine (8158) Details

China Regenerative Medicine International Limited, an investment holding company, researches and develops bio-medical and healthcare products, and medical techniques. It operates through three segments: Tissue Engineering, Stem Cell, and Cosmetics and Healthcare. The company offers ActivSkin, a tissue-engineered skin product; Acellular Corneal Stroma for use in therapeutic lamellar keratoplasty; Calcined Bovine Bone, a protein-detracted bone substitute material for inducing natural bone regeneration; and Acellular Anal Fistula Repair Stroma for anal fistula disease. It also researches and develops Recombinant Human Acellular Dermal Matrix, which is targeted on and applied for second degree burns; Selective Acellular Skin for use as a wound dressing; Acellular Amniotic Membrane, an anti-adhesion agent for muscle and tender rebuilding operations; and Absorbable Dental Membrane for jawbone defect restoration, which are in Stage II business development process. In addition, the company provides Cell Sheet-Autologous Chondrocyte Implantation, a medical technique for repairing knee and other related cartilage damages; and produces and sells cellular and stem cell therapy products. Further, it develops various cosmetic and skin care products for anti-aging, whitening, spot removal, and other applications on skin revival under the ascara brand, as well as anti-aging and healthcare solutions, and anti-aging and other natural supplement products. Additionally, it offers contract research organization services of drug screening, drug efficacy, and toxicity assays in the pre-clinical drug development; and produces and distributes 3D perfusion bioreactors and related consumables. The company was formerly known as China Bio-Med Regeneration Technology Limited and changed its name to China Regenerative Medicine International Limited in March 2015. China Regenerative Medicine International Limited was founded in 1995 and is headquartered in Wanchai, Hong Kong.

482 Employees
Last Reported Date: 12/14/16
Founded in 1995

china regenerative medicine (8158) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $1.3M
Vice Chairman and Compliance Officer
Total Annual Compensation: $406.0K
Compensation as of Fiscal Year 2016.
china regenerative medicine
China Regenerative Medicine International Limited, Board Meeting, Dec 02, 2016

China Regenerative Medicine International Limited, Board Meeting, Dec 02, 2016.

China Regenerative Medicine International Limited Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended October 31, 2016

China Regenerative Medicine International Limited announced unaudited consolidated earnings results for the second quarter and six months ended October 31, 2016. For the quarter, the company reported revenue of HKD 25,534,000 against HKD 3,421,000 a year ago. Loss before income tax was HKD 65,124,000 against HKD 27,074,000 a year ago. Loss for the period attributable to owners of the company was HKD 61,829,000 or 0.352 cents basic per share against HKD 23,203,000 or 0.132 cents basic per share a year ago. For the six months, the company reported revenue of HKD 28,254,000 against HKD 5,009,000 a year ago. Loss before income tax was HKD 147,318,000 against HKD 75,295,000 a year ago. Loss for the period attributable to owners of the company was HKD 138,184,000 or 0.786 cents basic per share against HKD 67,806,000 or 0.398 cents basic per share a year ago. Net cash used in operating activities was HKD 473,472,000 against HKD 169,874,000 a year ago. The overall increase in revenue was primarily attributable to an increase in revenue in both the tissue engineering and cosmetic and healthcare segments.

China Regenerative Medicine International Limited to Report First Half, 2017 Results on Dec 14, 2016

China Regenerative Medicine International Limited announced that they will report first half, 2017 results on Dec 14, 2016

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

8158 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 8158.
View Industry Companies
 

Industry Analysis

8158

Industry Average

Valuation 8158 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 89.7x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 57.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHINA REGENERATIVE MEDICINE, please visit www.crmi.hk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.